Jordânia Ferreira Martins,João Pedro Vasconcelos Paolinelli,Ricardo Augusto Dos Santos Silva et al.
Jordânia Ferreira Martins et al.
BackgroundAlthough the role of pharmacists in pediatric oncology is well established, scientific production explicitly characterizing the services provided in this field remains limited.ObjectiveTo map studies on pharmaceutical services in ...
Establishing a standardized clinical thinking model for oncology pharmacy outpatients in China: A mixed-method study [0.03%]
建立中国肿瘤药学门诊规范化临床思维模型的混合方法研究
Chao Li,Fenfen Gu,Jinlian Zhang et al.
Chao Li et al.
BackgroundOncology pharmacy clinics play a crucial role in improving medication adherence, managing drug-related problems (DRPs), enhancing quality of life, and reducing costs. However, standardized protocols for such clinics are currently ...
A cross-sectional survey on pharmacists' protection against hazardous drugs in China based on USP , NIOSH and ISOPP standards: Comparative analysis and improvement suggestions [0.03%]
基于USP、NIOSH和ISOPP标准的我国药学人员危害药物防护现状横断面调查：比较分析与改进建议
Hongyan He,Jingwei Wang,Shuyun Chen et al.
Hongyan He et al.
ObjectiveThis study aimed to benchmark the protective practices of intravenous admixture pharmacists in Chinese tertiary hospitals against international standards, including USP , the National Institute for Occupational Safety and Health (N...
Updates in the pharmacologic management of various Castleman disease subtypes: A comprehensive review [0.03%]
各种卡斯特曼病亚型药理学管理的最新进展：全面综述
Victor M Samperio,Sujay Singh,Mahum Zahid et al.
Victor M Samperio et al.
ObjectiveTo review current pharmacologic strategies for Castleman disease (CD), integrating contemporary understanding of disease biology, diagnostic subclassification, and therapeutic approaches across unicentric Castleman disease (UCD); H...
Personalised treatment in hpv-positive oropharyngeal squamous cell cancer: Insights from molecular biology to clinical trials [0.03%]
从分子生物学至临床试验角度解析人乳头瘤病毒阳性的口腔扁平细胞癌的个性化治疗
Kumar Masum,Balakeshwa Ramaiah
Kumar Masum
ObjectiveTo review current evidence on the epidemiology, molecular biology, and evolving treatment strategies of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), with particular emphasis on treatment de-esc...
Adjuvant olaparib real world data for BRCA positive, HER2-negative high-risk early breast cancer patients in the United Kingdom [0.03%]
英国BRCA阳性、HER2阴性高危早期乳腺癌患者奥拉帕利辅助治疗真实世界数据
Milly Finch,Carl Booth,Suzanne Frank et al.
Milly Finch et al.
IntroductionSince 2023 olaparib has been commissioned in the United Kingdom for breast cancer for patients with breast cancer gene 1 and 2 (BRCA1 and 2) positive, human epidermal growth factor receptor 2 (HER2)-negative, high-risk early dis...
Analysing compliance with calcium and vitamin D supplementations in cancer patients receiving bone resorptive agents [0.03%]
分析接受骨吸收剂治疗的癌症患者钙和维生素D补充剂的依从性
Jermaine Coward,Ashleigh Kate Smith
Jermaine Coward
ObjectiveTo assess patient-reported compliance with calcium and vitamin D supplementation and identify barriers in oncology patients prescribed bone resorptive therapy.MethodsA multicentre observational study was conducted across several pr...
Pharmacist-led pre-infusion screening using absolute lymphocyte count and neutrophil-to-lymphocyte ratio before immune checkpoint inhibitor therapy: A practice proposal [0.03%]
基于绝对淋巴细胞计数和中性粒细胞/淋巴细胞比值的药剂师主导免疫检查点抑制剂治疗前输注筛查：实践建议
Woei Jye Ong
Woei Jye Ong
BackgroundImmune checkpoint inhibitor (ICI) eligibility is primarily guided by tumor-centric biomarkers that do not fully account for the host's systemic immune competence. Emerging evidence suggests that readily available hematologic indic...
Knowledge, attitudes and perceptions of healthcare professionals and patients towards biosimilars in Singapore [0.03%]
新加坡医疗专业人员和患者对生物类似药的知识、态度和认知状况
Felicia Ong,Hui Hui Rachael Faithful Tan,Jo Lene Leow et al.
Felicia Ong et al.
ObjectiveBiosimilars offer a cost-effective alternative to biologics. Despite high (>95%) adoption in Singapore, gaps remain in healthcare professionals' (HCPs) and patients' knowledge and confidence. This study aims to assess the knowledge...
Pre-emptive DPYD genotyping and fluoropyrimidine dose optimisation: Dose tolerance and survival in cancer patients [0.03%]
DPYD基因分型及氟尿嘧啶类药物剂量优化在癌症患者中的应用：耐受性和生存率研究
Sarah Glewis,Senthil Lingaratnam,Tim Spelman et al.
Sarah Glewis et al.
IntroductionDespite evidence for dose reductions in DPYD variant allele carriers; efficacy concerns remain; we examined survival and dose tolerance in Australian fluoropyrimidine (FP) treated patients.MethodsData originated from the multi-c...